Mitra Biotech is a global leader in advancing personalized cancer treatment and empowering drug development & discovery. Our phenotypic CANscript platform delivers powerful insight for our biopharma partners. Because CANscript conserves the native tumor microenvironment and delivers 1:1 clinical correlation, it can be used to predict response of an indication to a specific drug (or drug combination), or to better understand MOA of a given compound.
KWS BioTest is an established CRO providing a wide range of drug discovery services spanning preclinical development from early cell biology, through efficacy models toclinical sample analysis. KWS BioTest specialises in immunology CRO services for the development of small molecules, biologics and ADCs. If you have a programme aimed at modifying the immune response, we can work with you to design and carry out your R&D to get you where you want to go.
Immudex. Based in Copenhagen, Denmark with North American operations based in Fairfax, Virginia, Immudex manufactures MHC Dextramers, the leading MHC multimer reagent for the detection of antigen-specific T cells. Under an agreement with the US Cancer Immunotherapy Consortium (CIC) and the European Cancer Immunotherapy Consortium (CIMT), Immudex also provides MHC Multimer and Elispot proficiency panel services worldwide.